157 related articles for article (PubMed ID: 3259355)
1. [Synovial level of interleukin 1 and C3a in chronic polyarthritis, psoriatic arthritis and activated arthritis].
Hermann E; Vogt P; Hagmann W; Dunky A; Müller W
Z Rheumatol; 1988; 47(1):20-5. PubMed ID: 3259355
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of C1q binding to antigen-antibody complexes by a factor in rheumatoid arthritis serum.
Niven IP; Whaley K
Rheumatol Int; 1986; 6(5):205-8. PubMed ID: 3492025
[TBL] [Abstract][Full Text] [Related]
3. Association of C1q- and conglutinin-binding immune complexes with high consumption of alpha-2-macroglobulin in synovial fluids of patients with rheumatoid arthritis.
Borth W; Menzel JE
Int Arch Allergy Appl Immunol; 1984; 75(1):92-6. PubMed ID: 6204949
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation.
Kotake S; Sato K; Kim KJ; Takahashi N; Udagawa N; Nakamura I; Yamaguchi A; Kishimoto T; Suda T; Kashiwazaki S
J Bone Miner Res; 1996 Jan; 11(1):88-95. PubMed ID: 8770701
[TBL] [Abstract][Full Text] [Related]
5. Complement activation in seropositive and seronegative rheumatoid arthritis. 125I-C1q binding capacity and complement breakdown products in serum and synovial fluid.
Lambert PH; Nydegger UE; Perrin LH; McCormic J; Fehr K; Miescher PA
Rheumatology; 1975; 6():52-9. PubMed ID: 1202608
[TBL] [Abstract][Full Text] [Related]
6. Terminal complement complexes and C1/C1 inhibitor complexes in rheumatoid arthritis and other arthritic conditions.
Oleesky DA; Daniels RH; Williams BD; Amos N; Morgan BP
Clin Exp Immunol; 1991 May; 84(2):250-5. PubMed ID: 2025952
[TBL] [Abstract][Full Text] [Related]
7. Correlation of synovial fluid interleukin 6 (IL-6) activities with IgG concentrations in patients with inflammatory joint disease and osteoarthritis.
Hermann E; Fleischer B; Mayet WJ; Poralla T; Meyer zum Büschenfelde KH
Clin Exp Rheumatol; 1989; 7(4):411-4. PubMed ID: 2591114
[TBL] [Abstract][Full Text] [Related]
8. Circulating complement breakdown products in patients with rheumatoid arthritis. Correlation between plasma C3d, circulating immune complexes, and clinical activity.
Nydegger UE; Zubler RH; Gabay R; Joliat G; Karagevrekis CH; Lambert PH; Miescher PA
J Clin Invest; 1977 May; 59(5):862-8. PubMed ID: 853126
[TBL] [Abstract][Full Text] [Related]
9. C1 inactivator-C1s complexes in inflammatory joint disease.
Inman RD; Harpel PC
Clin Exp Immunol; 1983 Sep; 53(3):521-8. PubMed ID: 6604603
[TBL] [Abstract][Full Text] [Related]
10. [Complement (C3)-activating material in synovial fluid from patients with rheumatoid arthritis].
Stojan B
Z Rheumatol; 1981; 40(5):208-12. PubMed ID: 6914866
[TBL] [Abstract][Full Text] [Related]
11. Synovial fluid levels of anti-cyclic citrullinated peptide antibodies and IgA rheumatoid factor in rheumatoid arthritis, psoriatic arthritis, and osteoarthritis.
Caspi D; Anouk M; Golan I; Paran D; Kaufman I; Wigler I; Levartovsky D; Litinsky I; Elkayam O
Arthritis Rheum; 2006 Feb; 55(1):53-6. PubMed ID: 16463412
[TBL] [Abstract][Full Text] [Related]
12. Interaction between fibronectin and C1q in rheumatoid synovial fluid and normal plasma.
Carsons SE; Schwartzman S; Diamond HS; Berkowitz E
Clin Exp Immunol; 1988 Apr; 72(1):37-42. PubMed ID: 3135129
[TBL] [Abstract][Full Text] [Related]
13. Immunofluorescence studies for immunoglobulins and complement C3 in synovial joint membranes in psoriatic arthritis.
Fyrand O; Mellbye OJ; Natvig JB
Clin Exp Immunol; 1977 Sep; 29(3):422-7. PubMed ID: 338220
[TBL] [Abstract][Full Text] [Related]
14. Complement activating properties of complexes containing rheumatoid factor in synovial fluids and sera from patients with rheumatoid arthritis.
Elson CJ; Carter SD; Cottrell BJ; Scott DG; Bacon PA; Wallington TB
Clin Exp Immunol; 1985 Feb; 59(2):285-92. PubMed ID: 3978872
[TBL] [Abstract][Full Text] [Related]
15. Elevated expression of interleukin-7 receptor in inflamed joints mediates interleukin-7-induced immune activation in rheumatoid arthritis.
Hartgring SA; van Roon JA; Wenting-van Wijk M; Jacobs KM; Jahangier ZN; Willis CR; Bijlsma JW; Lafeber FP
Arthritis Rheum; 2009 Sep; 60(9):2595-605. PubMed ID: 19714586
[TBL] [Abstract][Full Text] [Related]
16. Elevated C3 anaphylatoxin levels in synovial fluids from patients with rheumatoid arthritis.
Moxley G; Ruddy S
Arthritis Rheum; 1985 Oct; 28(10):1089-95. PubMed ID: 3876836
[TBL] [Abstract][Full Text] [Related]
17. Complement C3 cleavage product in synovial fluids detected by immunofixation.
Partsch G; Bauer K; Bröll H; Petera P; Dunky A; Merétey K
Z Rheumatol; 1991; 50(2):82-5. PubMed ID: 1872046
[TBL] [Abstract][Full Text] [Related]
18. Relative contribution of contact and complement activation to inflammatory reactions in arthritic joints.
Abbink JJ; Kamp AM; Nuijens JH; Erenberg AJ; Swaak AJ; Hack CE
Ann Rheum Dis; 1992 Oct; 51(10):1123-8. PubMed ID: 1444625
[TBL] [Abstract][Full Text] [Related]
19. The pathogenesis of arthritis in Lyme disease: humoral immune responses and the role of intra-articular immune complexes.
Hardin JA; Steere AC; Malawista SE
Yale J Biol Med; 1984; 57(4):589-93. PubMed ID: 6334939
[TBL] [Abstract][Full Text] [Related]
20. C1 activation, with C1q in excess of functional C1 in synovial fluid from patients with rheumatoid arthritis.
Sjöholm AG; Berglund K; Johnson U; Laurell AB; Sturfelt G
Int Arch Allergy Appl Immunol; 1986; 79(2):113-9. PubMed ID: 3484727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
